60 reports of this reaction
1.3% of all METHYLENE BLUE reports
#20 most reported adverse reaction
BRADYCARDIA is the #20 most commonly reported adverse reaction for METHYLENE BLUE, manufactured by American Regent, Inc.. There are 60 FDA adverse event reports linking METHYLENE BLUE to BRADYCARDIA. This represents approximately 1.3% of all 4,684 adverse event reports for this drug.
Patients taking METHYLENE BLUE who experience bradycardia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BRADYCARDIA is a less commonly reported adverse event for METHYLENE BLUE, but still significant enough to appear in the safety profile.
In addition to bradycardia, the following adverse reactions have been reported for METHYLENE BLUE:
The following drugs have also been linked to bradycardia in FDA adverse event reports:
BRADYCARDIA has been reported as an adverse event in 60 FDA reports for METHYLENE BLUE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BRADYCARDIA accounts for approximately 1.3% of all adverse event reports for METHYLENE BLUE, making it a notable side effect.
If you experience bradycardia while taking METHYLENE BLUE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.